{{Drugbox
| verifiedrevid = 447917039
| IUPAC_name = (4''R'')-1-acetyl-4-hydroxy-<small>L</small>-proline
| image = Oxaceprol.svg
| width = 200px

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|oxaceprol}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status =  
| routes_of_administration =  

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 33996-33-7
| ATC_prefix = D11
| ATC_suffix = AX09
| ATC_supplemental =   {{ATC|M01|AX24}}
| PubChem = 65784
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = Q0XV76B96L
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07215
| ChemSpiderID      = 59203
| ChEMBL = 1407356

<!--Chemical data-->
| C=7 | H=11 | N=1 | O=4 
| molecular_weight = 172.159 g/mol
| smiles            = CC(=O)N1C[C@@H](C[C@H]1C(=O)O)O
| StdInChI          = 1S/C7H11NO4/c1-4(9)8-3-5(10)2-6(8)7(11)12/h5-6,10H,2-3H2,1H3,(H,11,12)/t5-,6+/m1/s1
| StdInChIKey       = BAPRUDZDYCKSOQ-RITPCOANSA-N
| synonyms = <small>(2''S'',4''R'')-1-acetyl-4-hydroxypyrrolidine-2-carboxylic acid</small>
}}
'''Oxaceprol''' is an anti-inflammatory drug used in the treatment of [[osteoarthritis]].<ref name="pmid10791619">{{cite journal |author=Herrmann G |title=Oxaceprol is a well-tolerated therapy for osteoarthritis with efficacy equivalent to diclofenac |journal=Clin. Rheumatol. |volume=19 |issue=2 |pages=99â€“104 |year=2000 |pmid=10791619 |doi=10.1007/s100670050025 |name-list-format=vanc|author2=Steeger D |author3=Klasser M |display-authors=3 |last4=Wirbitzky |first4=J. |last5=f&#x000Fc;Rst |first5=M. |last6=Venbrocks |first6=R. |last7=Rohde |first7=H. |last8=Jungmichel |first8=D. |last9=Hildebrandt |first9=H. D.}}</ref> It is derived from [[L-proline]], a DNA-encoded [[amino acid]]. The active effect of Oxaceprol is to inhibit the adhesion and migration of [[white blood cell]]s.<ref name="Clayton2007"/>

==References==
{{reflist|refs=
<ref name="Clayton2007">{{Citation
 | first1    = James J.
 | last1     = Clayton
 | title     = Nutraceuticals in the Management of Osteoarthritis
 | journal   = Orthopedics
 |date=August 2007
 | volume    = 30
 | issue     = 8
 | url       = http://www.healio.com/orthopedics/journals/ORTHO/%7BD4DA9AAE-37CE-4E4A-9C5E-B518F4CFC952%7D/Nutraceuticals-in-the-Management-of-Osteoarthritis
 | accessdate= 2013-06-08
 | postscript= .
}}</ref>
}}

{{Other dermatological preparations}}
{{Anti-inflammatory and antirheumatic products}}

[[Category:Pyrrolidines]]
[[Category:Acetamides]]
[[Category:Alcohols]]
[[Category:Amino acid derivatives]]

{{musculoskeletal-drug-stub}}
{{dermatologic-drug-stub}}